Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

SAN FRANCISCO -- Menopause hormone therapy (MHT) was tied to a weight-loss boost in postmenopausal women taking a weight loss ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

Tirzepatide has emerged as the most effective treatment for lowering blood sugar and promoting weight loss in people with ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

In this cohort study, the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) semaglutide and tirzepatide was associated with a lower risk of dementia, stroke, and all-cause mortality in ...